Recasts paragraph 1 and updates shares

May 11 (Reuters) - Hims & Hers Health HIMS.N on Monday missed Wall Street estimates for first-quarter revenue and reported a surprise loss due to lower spending per subscriber and weakness in its U.S. business, sending its shares down about 10% in after-market trading.

The company has been shifting its strategy toward personalized treatments, amid tightening regulatory scrutiny.

The U.S. Food and Drug Administration has moved to restrict the compounding of copycat versions of GLP-1 drugs, and earlier referred Hims to the Department of Justice over potential violations, sending its shares lower.

"In the first quarter, we made a strategic pivot that expanded our assortment of branded GLP-1 products, and early demand signals show our consumer reach broadening meaningfully," said Yemi Okupe, Chief Financial Officer, explaining the fall in monthly revenue per average subscriber to $80 from $85 a year earlier.

Meanwhile, the company raised its full-year revenue forecast and projected stronger second-quarter sales above estimates.

Revenue for the first quarter came in at $608.1 million, below analysts' expectations of $616.85 million.

The company also reported a loss of 40 cents per share, compared with analysts' estimate for a profit of 4 cents per share.

The company now expects its annual revenue between $2.8 billion and $3 billion, compared with its previous forecast of $2.7 billion to $2.9 billion.

In March, Hims said it would partner with Novo Nordisk NOVOb.CO to offer its blockbuster weight-loss drug, Wegovy, on its platform, ending a legal dispute between the companies.

The dispute had followed Hims' launch of a low-cost compounded alternative to Wegovy, which it has since discontinued.

Hims expects second-quarter revenue in the range of $680 million to $700 million, compared with analysts' average estimate of $642.95 million, according to data compiled by LSEG.